Current impact of age and comorbidity assessment on prostate cancer treatment choice and over/undertreatment risk. En savoir plus sur Current impact of age and comorbidity assessment on prostate cancer treatment choice and over/undertreatment risk.
Localized chromophobe carcinomas treated by nephron-sparing surgery have excellent oncologic outcomes. En savoir plus sur Localized chromophobe carcinomas treated by nephron-sparing surgery have excellent oncologic outcomes.
Focal therapy as primary treatment for localized prostate cancer: definition, needs and future. En savoir plus sur Focal therapy as primary treatment for localized prostate cancer: definition, needs and future.
Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy. En savoir plus sur Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy.
Does teaching of robotic partial nephrectomy affect renal function and perioperative outcomes? En savoir plus sur Does teaching of robotic partial nephrectomy affect renal function and perioperative outcomes?
External validation of a nomogram for identification of pathologically favorable disease in intermediate risk prostate cancer patients. En savoir plus sur External validation of a nomogram for identification of pathologically favorable disease in intermediate risk prostate cancer patients.
Kallikreins Panel for Prostate Cancer Aggressiveness Prediction: More Is Not Enough. En savoir plus sur Kallikreins Panel for Prostate Cancer Aggressiveness Prediction: More Is Not Enough.
[Active surveillance of prostate cancer]. En savoir plus sur [Active surveillance of prostate cancer].
The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgery. En savoir plus sur The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgery.
What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer? En savoir plus sur What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?